Skip to content

Donor Funding: $173,844
Cancer Type: Leukaemia
Cancer Stage: Treatment
Funded in: 2021, 2022

Prof Deborah White
The University of Adelaide

Acute Lymphoblastic Leukaemia (ALL) treatment is toxic, expensive and ineffective for many patients, though the reasons for this are unclear. Even when successful, treatment can lead to debilitating late-effects, and an increased risk of early mortality. The gut microbiome is increasingly recognised for its role in cancer. Here, we will investigate the role of the microbiome in ALL treatment response and late-effects, and develop approaches to improve outcomes across the life-course.